- Ayurcann (AYUR) has entered into supply agreements with Cannmart and Patient Choice, two medical cannabis product suppliers
- Ayurcann entered into separate twelve-month agreements with the companies with the option to renew
- In each case, Ayurcann will provide manufactured products for resale into the medical cannabis market
- Cannmart provides a diverse selection of hand-picked products from federally-licensed cultivators
- Patient Choice provides convenient access to high-quality and reasonably-priced medical cannabis products
- Ayurcann Holdings provides custom processes and pharma-grade products for the adult use and medical cannabis industry in Canada
- Ayurcann (AYUR) is down by 7.89 per cent and is currently trading at $0.175 per share
Ayurcann (AYUR) has entered into supply agreements with Cannmart and Patient Choice, two medical cannabis product suppliers.
Cannmart and Ayurcann have entered into a twelve-month supply agreement with the option to renew, under which Ayurcann will provide Cannmart with manufactured products for resale into the medical cannabis market.
The agreement between Ayurcann and Cannmart became effective on April 15, 2021.
Patient Choice and Ayurcann have also entered into a twelve-month supply agreement with the option to renew. Patient Choice will operate a platform that facilitates direct-to-patient sales of medical cannabis on a drop-shipped non-possession basis.
The agreement between Ayurcann and Patient Choice was entered into on December 17, 2020.
Some of the products Ayurcann will manufacture and supply include the Xplor Pure CBD 1000 Tincture, the Fuego Vena Grad 1 g Vape Cartridge and the Xplor Balanced 250 Tincture.
Igal Sudman, CEO of Ayurcann, commented,
“We are thrilled by this opportunity as we believe these agreements further cement our positioning in the industry as a top-quality supplier for leading cannabis brands and direct-to-medical patients.
We have the ability to formulate, manufacture and package quality products at affordable prices and have shown an ability to work with our clients to create products that will resonate in the marketplace.”
Cannmart provides a diverse selection of hand-picked products from federally-licensed cultivators.
Patient Choice provides convenient access to high-quality and reasonably-priced medical cannabis products.
Ayurcann Holdings provides custom processes and pharma-grade products for the adult use and medical cannabis industry in Canada.
Ayurcann (AYUR) is down by 7.89 per cent and is currently trading at $0.175 per share as of 10:27 am ET.